Similarly, a phase III metastatic melanoma trial, which compared peptide vaccination in combination with IL-2 therapy to IL-2 therapy alone, showed a significant improvement in overall response rate and progression-free survival in those patients who had received the vaccine [112]. This evidence concerns the gene IL2 and metastatic melanoma.